Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)
February 01 2023 - 9:53AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1
to
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of February, 2023
011-36000
(Commission File Number)
XTL Biopharmaceuticals Ltd.
(Exact name of Registrant as specified in its charter)
5 Badner St.
Ramat Gan, Israel, 5218102
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):_____
EXPLANATORY NOTE
XTL Biopharmaceuticals Ltd. (the
“Company”) is filing this Amendment No. 1 to amend and restate its Report on Form 6-K and all exhibits furnished with the
U.S. Securities and Exchange Commission on January 20, 2023 (the “Original Report”). This Amendment No. 1 is being filed solely
for the purpose of amending the meeting time from 3:00 PM (Israel Time), on February 23, 2023 to 10:00 AM (Israel Time), on February
23, 2023.
Exhibit Index
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
XTL BIOPHARMACEUTICALS LTD. |
| |
|
| Date: February 1, 2023 |
/s/ Shlomo Shalev |
| |
Shlomo Shalev
Chief Executive Officer |
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Mar 2024 to Apr 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Apr 2023 to Apr 2024
